Online inquiry

IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9093MR)

This product GTTS-WQ9093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&PMEL gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001200053.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6490
UniProt ID P07766; P40967
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9093MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15503MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ7929MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ153MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ12106MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ11817MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ1592MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ10004MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ13122MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW